Call for Nominations:  ANCO's Board of Directors

• In accordance with the by-laws of the Association of Northern California, the ANCO Board of Directors hereby issues a call for a nominations for members of the Board of Directors. (Read the job description).

  To nominate (or self-nominate) a candidate for the ANCO's Board of Directors, please use the form below by 11:00pm, October 15, 2026.

  Click here for a complete list of the current board of directors.

Submit a Nomination

Institutional Member News

• UC Davis Comprehensive Cancer Center - Clinical Trials

  PHII-254 – Sinonasal Squamous Cell Carcinoma (Head & Neck) Randomized Phase 2 study adding Cemiplimab to chemotherapy before surgery Compares chemo (carboplatin + paclitaxel) with vs. without cemiplimab given before surgery in patients with sinonasal squamous cell cancer, to see if it's more effective at stopping cancer growth/spread than chemo alone. Website: https://clinicaltrials.gov/study/NCT07281417 Contact: UC Davis Comprehensive Cancer Center, Office of Clinical Research — OCRReferral@health.ucdavis.edu | 916-382-6970

  D7630C00001 – Breast Cancer (TNBC) Phase III study of Dato-DXd ± durvalumab vs. chemo + pembrolizumab Compares Dato-DXd with durvalumab against standard chemotherapy plus pembrolizumab in patients with PD-L1 positive, locally recurrent inoperable or metastatic triple-negative breast cancer, looking at progression-free survival, overall survival, and quality of life. Website: https://clinicaltrials.gov/study/NCT06103864 Contact: UC Davis Comprehensive Cancer Center, Office of Clinical Research — OCRReferral@health.ucdavis.edu | 916-382-6970

  NRG-GI012 – Hepatocellular Cancer (HCC) Phase III study of IO-based systemic treatment ± liver SBRT (HELIO-RT) Evaluates whether adding liver SBRT to first-line immunotherapy-based systemic treatment improves outcomes in patients with advanced hepatocellular carcinoma with macrovascular invasion. Website: https://clinicaltrials.gov/study/NCT07166406 Contact: UC Davis Comprehensive Cancer Center, Office of Clinical Research — OCRReferral@health.ucdavis.edu | 916-382-6970

Practice Management & Operations

• Mednet has a new AI-powered tool, TrialMatch, helps oncologists quickly match patients with actively enrolling clinical trials using natural language searches.

Read More

• A recent NCCN survey highlights persistent generic chemotherapy shortages impacting cancer centers nationwide, affecting critical agents like carboplatin and cisplatin—read more here.

Read More

The NCCN Policy & Advocacy

NCCN Oncology Clinical Trials Survey

NCCN is studying how policy and practice changes can strengthen collaboration between academic and community oncologists to improve representative enrollment in clinical trials.

• Survey Link: Take the Survey

• Time Commitment: ~10 minutes

• Deadline: October 12, 2026

• Confidentiality: All responses are confidential, unlinked to your identity, and approved by the Pearl Institutional Review Board.

• Questions? Contact Ashley Orr (orr@nccn.org) or Taneal Carter (carter@nccn.org), both cc’ed on this email.

National Press Club for our expanded two-day summit, featuring a welcome reception on night one!

• Schedule & Locations:

  • Monday, Oct 5 (Evening): Welcome Networking Reception at the JW Marriott

  • Tuesday, Oct 6: Policy Summit at the National Press Club

• Keynote Speakers:

  • Dr. Anthony Letai, Director of the NCI

  • Captain Jacqueline Miller, MD, Acting Division Director, CDC Division of Cancer Prevention and Control

• In-Person Attendance for SOSF Members: We have a few remaining slots available to fully cover registration, travel, and lodging for SOSF members. Please reply to this email if you are interested in attending in person.

• Virtual Attendance: Free virtual registration is available to all using promo code GD2026.

• Agenda: View the full schedule and speaker lineup here.

Corporate Member News

• Bristol Myers Squibb invites you to an educational discussion on Patient Outcomes with a CELMoD (ZENBEXUS™) led by Dr. Saeed Sadeghi (UCLA). Topics include the CELMoD mechanism, clinical efficacy and safety data in RRMM, patient selection, and real-world management. Date & Time: Thursday, October 1, 2026 @ 6:30 PM PT
  

• The FDA granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
  

Read More

• The FDA approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Inluriyo and Verzenio are manufactured by Eli Lilly and Company.

• The FDA granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
  

• The FDA approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells. 

Read More

• The FDA approved Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in first-Line HER2+ Advanced Gastroesophageal Adenocarcinoma.

Read More

• The FDA approved BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET).

Read More

• Revolution Medicine invites you to their upcoming National Broadcast on September 30th 2026 at 6pm in San Francisco.

Click Here For More Details

Reibursement Updates